Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Immunitybio inc symbols : FNCTF save search
ImmunityBio Announces Presentation at ASCO GI 2023 of Fully Enrolled Trial in Third-Line and Greater Pancreatic Cancer and Update on FDA Type B Meetings Regarding Paths to Registration
Published: 2023-01-19 (Crawled : 14:20) - nantkwest.com
IBRX | $4.945 -6.17% -6.57% 4.2M
|
Manufacturing
|
| O: -1.1%
H: 1.11%
C: 0.22%
fda trial presentation asco update cancer pancreatic
ImmunityBio Announces QUILT Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer at the 2022 American Society of Clinical Oncology Annual Meeting
Published: 2022-06-06 (Crawled : 13:00) - nantkwest.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: 0.17%
H: 0.0%
C: 0.0%
IBRX | $4.945 -6.17% -6.57% 4.2M
|
Manufacturing
|
| O: 14.42%
H: 1.88%
C: -4.29%
trial cancer pancreatic bladder
ImmunityBio Announces Results of Phase 2 Metastatic Pancreatic Cancer Trial at ASCO GI With Median Overall Survival of 6.3 Months in Patients With Third-Line Disease, More Than Doubling Historical Survival
Published: 2022-01-18 (Crawled : 00:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: -0.4%
H: 0.0%
C: -0.58%
IBRX | $4.945 -6.17% -6.57% 4.2M
|
Manufacturing
|
| O: -1.27%
H: 0.0%
C: 0.0%
phase 2 trial disease media asco cancer pancreatic
CytRx Highlights ImmunityBio's Completion of Enrollment in Phase 2 Study of Advanced Metastatic Pancreatic Cancer Treatment
Published: 2021-10-14 (Crawled : 13:00) - biospace.com/
IBRX | $4.945 -6.17% -6.57% 4.2M
|
Manufacturing
|
| O: 0.99%
H: 8.76%
C: 4.24%
treatment phase 2 cancer pancreatic pancreas enroll
ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients—90% of Patients Have Exceeded Historical Survival Rates to Date
Published: 2021-10-13 (Crawled : 13:00) - nantkwest.com
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: -0.18%
H: 0.0%
C: 0.0%
IBRX | $4.945 -6.17% -6.57% 4.2M
|
Manufacturing
|
| O: 0.54%
H: 0.59%
C: -2.15%
phase 2 cancer vaccine pancreatic pancreas enroll
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.